290 related articles for article (PubMed ID: 35962349)
1. Zishen pingchan granules combined with pramipexole in the improvement of depressive symptoms in Parkinson's disease: a prospective, multicenter, randomized, double-blind, controlled clinical study.
Ning H; Zhou H; Ren J; Zhou G; Yang N; Wang Z; Yuan C; Tian Z; Chen J; Shen L; Zheng H; Zhao Y; Wang H; Liu W; Liu Z
J Transl Med; 2022 Aug; 20(1):357. PubMed ID: 35962349
[TBL] [Abstract][Full Text] [Related]
2. Effect of Zishen pingchan granules combined with pramipexole on serum BDNF, IL-1β, IL-6, CRP, TNF-α levels in depressed patients with Parkinson's disease: Results of a randomized, double-blind, controlled study.
Ning H; Zhou H; Yang N; Ren J; Wang H; Liu W; Zhao Y
Exp Gerontol; 2023 Oct; 182():112295. PubMed ID: 37734668
[TBL] [Abstract][Full Text] [Related]
3. Pingchan granule for depressive symptoms in parkinson's disease: A randomized, double-blind, placebo-controlled trial.
Gu SC; Zhou J; Ye Q; Yuan CX
J Integr Med; 2021 Mar; 19(2):120-128. PubMed ID: 33446472
[TBL] [Abstract][Full Text] [Related]
4. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
[TBL] [Abstract][Full Text] [Related]
5. Pingchan Granule for Motor Symptoms and Non-Motor Symptoms of Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study.
Gu SC; Ye Q; Wang CD; Zhao SR; Zhou J; Gao C; Zhang Y; Liu ZG; Yuan CX
Front Pharmacol; 2022; 13():739194. PubMed ID: 35281890
[No Abstract] [Full Text] [Related]
6. Traditional Chinese medicine syndrome differentiation and treatment by stages of Parkinson's disease: study protocol for a multicentre, randomized, double-blind, placebo-controlled clinical trial.
Hu Y; Gu S; Yuan X; Li H; Yuan C; Ye Q
Chin Med; 2022 Jun; 17(1):68. PubMed ID: 35698234
[TBL] [Abstract][Full Text] [Related]
7. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study.
Pinter MM; Pogarell O; Oertel WH
J Neurol Neurosurg Psychiatry; 1999 Apr; 66(4):436-41. PubMed ID: 10201413
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
Shen T; Ye R; Zhang B
Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.
Pogarell O; Gasser T; van Hilten JJ; Spieker S; Pollentier S; Meier D; Oertel WH
J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):713-20. PubMed ID: 12023411
[TBL] [Abstract][Full Text] [Related]
11. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group.
JAMA; 1997 Jul; 278(2):125-30. PubMed ID: 9214527
[TBL] [Abstract][Full Text] [Related]
13. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
[TBL] [Abstract][Full Text] [Related]
14. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial.
Schapira AH; Barone P; Hauser RA; Mizuno Y; Rascol O; Busse M; Salin L; Juhel N; Poewe W;
Neurology; 2011 Aug; 77(8):767-74. PubMed ID: 21832216
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.
Wong KS; Lu CS; Shan DE; Yang CC; Tsoi TH; Mok V
J Neurol Sci; 2003 Dec; 216(1):81-7. PubMed ID: 14607306
[TBL] [Abstract][Full Text] [Related]
16. Traditional Chinese medicine Pingchan granule for motor symptoms and functions in Parkinson's disease: A multicenter, randomized, double-blind, placebo-controlled study.
Gu SC; Shi R; Gaoag C; Yuan XL; Wu Y; Zhang Y; De Wang C; Fan RD; Chen X; Yuan CX; Ye Q
Phytomedicine; 2023 Jan; 108():154497. PubMed ID: 36283254
[TBL] [Abstract][Full Text] [Related]
17. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage.
Parkinson Study Group
Clin Neuropharmacol; 2007; 30(2):72-85. PubMed ID: 17414939
[TBL] [Abstract][Full Text] [Related]
18. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
Poewe W; Rascol O; Barone P; Hauser RA; Mizuno Y; Haaksma M; Salin L; Juhel N; Schapira AH;
Neurology; 2011 Aug; 77(8):759-66. PubMed ID: 21832218
[TBL] [Abstract][Full Text] [Related]
19. Comparison of nocturnal symptoms in advanced Parkinson's disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations.
Xiang W; Sun YQ; Teoh HC
Drug Des Devel Ther; 2018; 12():2017-2024. PubMed ID: 30013321
[TBL] [Abstract][Full Text] [Related]
20. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
